Molecular basis for serum resistance in Neisseria gonorrhoeae - PubMed (original) (raw)

Review

Molecular basis for serum resistance in Neisseria gonorrhoeae

P A Rice. Clin Microbiol Rev. 1989 Apr.

No abstract available

PubMed Disclaimer

Similar articles

• Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum.
  Rice PA, Vayo HE, Tam MR, Blake MS. Rice PA, et al. J Exp Med. 1986 Nov 1;164(5):1735-48. doi: 10.1084/jem.164.5.1735. J Exp Med. 1986. PMID: 3095479 Free PMC article.
• Mechanisms of stable serum resistance of Neisseria gonorrhoeae.
  Rice PA, Blake MS, Joiner KA. Rice PA, et al. Antonie Van Leeuwenhoek. 1987;53(6):565-74. doi: 10.1007/BF00415518. Antonie Van Leeuwenhoek. 1987. PMID: 3130793
• The interaction of naturally elaborated blebs from serum-susceptible and serum-resistant strains of Neisseria gonorrhoeae with normal human serum.
  Pettit RK, Judd RC. Pettit RK, et al. Mol Microbiol. 1992 Mar;6(6):729-34. doi: 10.1111/j.1365-2958.1992.tb01522.x. Mol Microbiol. 1992. PMID: 1574002
• Phase and antigenic variation of pili and outer membrane protein II of Neisseria gonorrhoeae.
  Sparling PF, Cannon JG, So M. Sparling PF, et al. J Infect Dis. 1986 Feb;153(2):196-201. doi: 10.1093/infdis/153.2.196. J Infect Dis. 1986. PMID: 2418125 Review. No abstract available.
• Gonococcal infection: a model of molecular pathogenesis.
  Britigan BE, Cohen MS, Sparling PF. Britigan BE, et al. N Engl J Med. 1985 Jun 27;312(26):1683-94. doi: 10.1056/NEJM198506273122606. N Engl J Med. 1985. PMID: 2860565 Review. No abstract available.

Cited by

• Antibody-Dependent Enhancement of Bacterial Disease: Prevalence, Mechanisms, and Treatment.
  Torres VVL, Coggon CF, Wells TJ. Torres VVL, et al. Infect Immun. 2021 Mar 17;89(4):e00054-21. doi: 10.1128/IAI.00054-21. Print 2021 Mar 17. Infect Immun. 2021. PMID: 33558319 Free PMC article. Review.
• Feasibility of Using a Luminescence-Based Method to Determine Serum Bactericidal Activity against Neisseria gonorrhoeae.
  Clow F, O'Hanlon CJ, Christodoulides M, Radcliff FJ. Clow F, et al. Vaccines (Basel). 2019 Nov 21;7(4):191. doi: 10.3390/vaccines7040191. Vaccines (Basel). 2019. PMID: 31766474 Free PMC article.
• Exploitation of Neisseria meningitidis Group B OMV Vaccines Against N. gonorrhoeae to Inform the Development and Deployment of Effective Gonorrhea Vaccines.
  Petousis-Harris H, Radcliff FJ. Petousis-Harris H, et al. Front Immunol. 2019 Apr 9;10:683. doi: 10.3389/fimmu.2019.00683. eCollection 2019. Front Immunol. 2019. PMID: 31024540 Free PMC article. Review.
• Both MisR (CpxR) and MisS (CpxA) Are Required for Neisseria gonorrhoeae Infection in a Murine Model of Lower Genital Tract Infection.
  Gangaiah D, Raterman EL, Wu H, Fortney KR, Gao H, Liu Y, Jerse AE, Spinola SM. Gangaiah D, et al. Infect Immun. 2017 Aug 18;85(9):e00307-17. doi: 10.1128/IAI.00307-17. Print 2017 Sep. Infect Immun. 2017. PMID: 28652307 Free PMC article.
• Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics.
  Ram S, Shaughnessy J, de Oliveira RB, Lewis LA, Gulati S, Rice PA. Ram S, et al. Pathog Dis. 2017 Jun 1;75(4):ftx049. doi: 10.1093/femspd/ftx049. Pathog Dis. 2017. PMID: 28460033 Free PMC article.

References

1. 1. J Clin Invest. 1987 Jul;80(1):78-87 - PubMed
2. 1. J Clin Invest. 1982 Jul;70(1):157-67 - PubMed
3. 1. Semin Arthritis Rheum. 1979 Feb;8(3):177-83 - PubMed
4. 1. Br J Vener Dis. 1982 Dec;58(6):363-5 - PubMed
5. 1. Infect Immun. 1987 Dec;55(12):3017-22 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations